About Palvella Therapeutics, Inc.
https://palvellatx.comPalvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
CEO
Wesley H. Kaupinen
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-04-23 | Reverse | 1:80 |
ETFs Holding This Stock
Summary
Showing Top 3 of 89
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Raymond James
Strong Buy
Canaccord Genuity
Buy
TD Cowen
Buy
Truist Securities
Buy
Chardan Capital
Buy
HC Wainwright & Co.
Buy
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
BVF INC/IL
Shares:1.16M
Value:$122.28M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:822.4K
Value:$86.6M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:722.4K
Value:$76.07M
Summary
Showing Top 3 of 102
About Palvella Therapeutics, Inc.
https://palvellatx.comPalvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $10.18M ▲ | $-11.35M ▼ | 0% | $-1.03 ▼ | $342K ▲ |
| Q2-2025 | $0 | $9.25M ▲ | $-9.47M ▼ | 0% | $-0.86 ▲ | $-8.12M ▼ |
| Q1-2025 | $0 | $7.87M ▲ | $-8.19M ▼ | 0% | $-3.68 ▼ | $-6.97M ▼ |
| Q3-2024 | $0 | $5.06M ▲ | $-6.78M ▼ | 0% | $-2.19 ▲ | $0 ▲ |
| Q2-2024 | $0 | $2.91M | $-4.17M | 0% | $-3.37 | $-3.12M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $63.57M ▼ | $66.94M ▼ | $28.25M ▲ | $38.68M ▼ |
| Q2-2025 | $70.43M ▼ | $73.75M ▼ | $25.97M ▲ | $47.78M ▼ |
| Q1-2025 | $75.63M ▲ | $79.44M ▲ | $23.86M ▲ | $55.58M ▲ |
| Q3-2024 | $19.36M ▼ | $20.52M ▼ | $4.25M ▼ | $16.27M ▼ |
| Q2-2024 | $19.73M | $25.05M | $6.35M | $18.7M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-11.35M ▼ | $0 ▲ | $0 | $0 ▼ | $-6.87M ▼ | $0 ▲ |
| Q2-2025 | $-9.47M ▼ | $-5.43M ▲ | $0 | $349K ▲ | $-5.19M ▼ | $-5.43M ▲ |
| Q1-2025 | $-8.19M ▼ | $-6.77M ▼ | $0 | $-1.2M ▼ | $56.26M ▲ | $-6.77M ▼ |
| Q1-2024 | $-2.54M ▲ | $-1.1M ▲ | $0 ▼ | $0 ▼ | $-1.1M ▲ | $-1.1M ▲ |
| Q4-2023 | $-4.58M | $-19.67M | $3.45M | $14K | $-15.5M | $-19.66M |
CEO
Wesley H. Kaupinen
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-04-23 | Reverse | 1:80 |
ETFs Holding This Stock
Summary
Showing Top 3 of 89
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Raymond James
Strong Buy
Canaccord Genuity
Buy
TD Cowen
Buy
Truist Securities
Buy
Chardan Capital
Buy
HC Wainwright & Co.
Buy
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
BVF INC/IL
Shares:1.16M
Value:$122.28M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:822.4K
Value:$86.6M
FRAZIER LIFE SCIENCES MANAGEMENT, L.P.
Shares:722.4K
Value:$76.07M
Summary
Showing Top 3 of 102